Older adults who got the mRNA-1283 COVID shot had fewer infections
☕ Includes a question for the family ↓
Infections and vaccines after 50Part of a story we are following · 10 articles · See every update
If you are an older adult, or you care about one, here is encouraging news about this season’s COVID shot. A new vaccine called mRNA-1283 was linked to fewer infections serious enough to need medical care.
In a study of 294,499 older US veterans, people who got the mRNA-1283 COVID vaccine had fewer medically treated COVID-19 infections than people who got the BNT162b2 vaccine: 0.16% versus 0.28%. They also had fewer hospital stays for COVID-19.
How the study worked
Researchers looked at US veterans aged 65 and older in the Veterans Health Administration system. They had all gotten either mRNA-1283 or BNT162b2 between August 27, 2025, and January 31, 2026, and were followed for up to 150 days. The study was published on November 2, 2026, in JAMA Netw Open. It was a retrospective cohort study, which means it looked back at health records, and the group was mostly men (94.2%), with an average age of 76.8.
To make the comparison fair, the team matched people by home county and by the week they got vaccinated. They then adjusted for age and health factors, so the two groups were as alike as possible.
What is mRNA-1283?
mRNA-1283 is a newer kind of mRNA COVID vaccine. It was first used in the 2025-2026 respiratory virus season. It is built around the parts of the virus’s spike, the knob on its surface, that the immune system notices most. The shot gives your body a set of instructions so it can recognize the spike quickly if the virus shows up.
BNT162b2 is another mRNA COVID vaccine. It was the comparison in this study.
What they found
The main measure was “medically attended COVID-19.” That means a positive test linked to medical care or antiviral treatment, or a primary COVID-19 diagnosis.
Among people with mRNA-1283, 86 of 55,349 had such an infection, which is 0.16%. Among people with BNT162b2, 672 of 239,150 did, which is 0.28%. That works out to an estimated relative vaccine effectiveness of 35.9%. In plain words, the mRNA-1283 group had about 36% fewer of these infections than the BNT162b2 group.
In absolute terms, the difference was 10.0 fewer infections for every 10,000 people.
Hospital stays showed a similar pattern. COVID-19 hospitalization happened in 11 people who got mRNA-1283 (0.02%) and in 114 people who got BNT162b2 (0.05%). The estimated relative effectiveness was 47.0%, so the mRNA-1283 group had roughly half as many hospital stays. The difference was 2.2 fewer hospitalizations for every 10,000 people.
The authors say these results suggest mRNA-1283 offers more meaningful protection for older adults at high risk of severe COVID-19. They also say the findings could help guide which vaccine is chosen each season.
What you can do today
When you book your COVID shot this season, ask the pharmacy or clinic which vaccine they carry. If mRNA-1283 is available, you can ask for it by name. If your pharmacy does not stock it, call another one nearby and ask the same question.
Talk about it at home
Scientists looked back at the health records of many older veterans who had gotten one of two COVID shots, and compared how many in each group later needed medical care for COVID. To keep it fair, they matched people who lived in the same county and got their shot the same week, a bit like comparing two teams that play on the same field on the same day. The newer shot gives the body a set of instructions to spot the virus’s spike, like showing a security guard a photo of someone to watch for.
Try it at home
Draw a silly made-up creature with a special hat, then let everyone draw their own creatures on scraps of paper and mix them all up. Show the picture to one person ahead of time, and see if they spot the hat creature faster than someone who never saw it.
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. Older adults who got the mRNA-1283 COVID shot had fewer infections. Mongevity. Published November 11, 2026. Accessed November 22, 2026. https://mongevity.science/immunity/2026/11/mrna-1283-covid-vaccine-fewer-infections-older-adults/Mongevity Desk. Older adults who got the mRNA-1283 COVID shot had fewer infections [Internet]. Mongevity; 2026 Nov 11 cited 2026 Nov 22]. Available from: https://mongevity.science/immunity/2026/11/mrna-1283-covid-vaccine-fewer-infections-older-adults/Mongevity Desk. (2026, November 11). Older adults who got the mRNA-1283 COVID shot had fewer infections. Mongevity. https://mongevity.science/immunity/2026/11/mrna-1283-covid-vaccine-fewer-infections-older-adults/
<a href="https://mongevity.science/immunity/2026/11/mrna-1283-covid-vaccine-fewer-infections-older-adults/">Older adults who got the mRNA-1283 COVID shot had fewer infections</a>
Free to share or quote with credit and a link.
Questions and answers
- What is the mRNA-1283 vaccine?
- It is a newer mRNA COVID vaccine that targets the parts of the virus's spike the immune system notices most. It was first used in the 2025-2026 respiratory virus season.
- Who was studied?
- US veterans aged 65 and older in the Veterans Health Administration system. 294,499 people were in the final matched group.
- How much lower were the infection rates?
- Medically treated COVID-19 occurred in 0.16% of people who got mRNA-1283 and 0.28% of people who got BNT162b2.
- Did hospital stays differ too?
- Yes. COVID-19 hospitalization occurred in 0.02% of the mRNA-1283 group and 0.05% of the BNT162b2 group.





